12.11USD-0.53%Mkt Cap: 1.01B USDP/E: —Last update: 2026-06-01
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the Un…
Industry Peers
BiotechnologyIndicators:|
Key Statistics
Company
Market Cap1.01B USD
Enterprise Value807.68M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-15.28M USD
Revenue/Share—
Last Price12.11 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees37
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS2210151005
Valuation
P/E (Trailing)—
P/E (Forward)-13.11
PEG—
EV/EBITDA-16.89
EV/Revenue—
P/S—
P/B4.34
EPS (TTM)-0.55
EPS (Forward)-0.95
52W Range
3.55037% of range26.95
52W High26.95 USD
52W Low3.550 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-24.97%
ROA-21.49%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-32.80M USD
CapEx (TTM)174.00K USD
FCF Margin—
FCF Yield-2.22%
Net Debt-235.88M USD
Net Debt/EBITDA4.93
Balance Sheet
Debt/Equity0.02
Current Ratio19.81
Quick Ratio19.65
Book Value/Sh2.862 USD
Cash/Share2.815 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Target (Mean)33.33 USD
Target Range27.00 USD – 42.00 USD
# Analysts6
Ownership
Shares Out.84.09M
Float72.79M
Insiders3.51%
Institutions85.13%
Short Interest
Short Ratio11.9d
Short % Float25.56%
Short % Out.22.49%
Shares Short18.91M
Short (prev mo.)16.93M
Technical
SMA 5014.60 (-17.0%)
SMA 20011.37 (+6.6%)
Beta0.94
S&P 52W Chg27.94%
Avg Vol (30d)1.63M
Avg Vol (10d)2.32M
Technical Indicators
RSI (14)38.4
MACD-0.8263
MACD Signal-0.6981
MACD Hist.-0.1282
BB Upper17.20 USD
BB Middle13.91 USD
BB Lower10.62 USD
BB Width47.28%
ATR (14)1.057 USD
Vol Ratio (20d)0.73x